Molecular subtypes, stem cells and heterogeneity: Implications for personalised therapy in glioma

Journal of Clinical Neuroscience

Volumn 22, Issue 8, 2015, Pages 1219-1226

  Morokoff, Andrew ^a   Ng, Wayne ^a   Gogos, Andrew ^a   Kaye, Andrew ^a  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Glioblastoma; Glioma stem cells; Mesenchymal; Molecular profiling; Personalised medicine; Proneural

Indexed keywords

CD133 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; HERMES ANTIGEN; ISOCITRATE DEHYDROGENASE 1; MUSASHI; NESTIN; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN P53; STEM CELL FACTOR; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; CANCER CLASSIFICATION; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOGENESIS; CELL DIFFERENTIATION; CELL HETEROGENEITY; CHROMOSOME 1P; CHROMOSOME 9Q; CHROMOSOME LOSS; CLONAL VARIATION; COMPARATIVE GENOMIC HYBRIDIZATION; CPG ISLAND; DNA METHYLATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENETIC ASSOCIATION; GLIOBLASTOMA; GLIOMA STEM CELL; HUMAN; IDH1 GENE; LONG TERM SURVIVAL; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PERSONALIZED MEDICINE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TELOMERE HOMEOSTASIS; TREATMENT RESPONSE; ADULT; AGED; BRAIN NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; GLIOMA; MALE; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; PROCEDURES; STEM CELL; STEM CELL TRANSPLANTATION;

ADULT; AGED; BRAIN NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; MALE; MIDDLE AGED; PRECISION MEDICINE; STEM CELL TRANSPLANTATION; STEM CELLS;

EID: 84939578542     PISSN: 09675868     EISSN: 15322653     Source Type: Journal    
DOI: 10.1016/j.jocn.2015.02.008     Document Type: Review

References (119)

1. P. Bailey, and H. Cushing A classification of the tumors of the glioma group on a histogenetic basis with a correlated study of prognosis 1926 JP Lippincott Philadelphia
2. R. Stupp, W.P. Mason, M.J. van den Bent, and et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 2005 987 996
3. D.N. Louis, H. Ohgaki, O.D. Wiestler, and et al. The 2007 WHO classification of tumours of the central nervous system Acta Neuropathol 114 2007 97 109
4. M.J. Bello, J.M. de Campos, M.E. Kusak, and et al. Molecular analysis of genomic abnormalities in human gliomas Cancer Genet Cytogenet 73 1994 122 129
5. S. Godard, G. Getz, M. Delorenzi, and et al. Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes Cancer Res 63 2003 6613 6625
6. P. Kleihues, and H. Ohgaki Primary and secondary glioblastomas: from concept to clinical diagnosis Neuro Oncol 1 1999 44 51
7. Cancer Genome Atlas Research Network Comprehensive genomic characterization defines human glioblastoma genes and core pathways Nature 455 2008 1061 1068
8. D.W. Parsons, S. Jones, X. Zhang, and et al. An integrated genomic analysis of human glioblastoma multiforme Science 321 2008 1807 1812
9. H. Yan, D.W. Parsons, G. Jin, and et al. IDH1 and IDH2 mutations in gliomas N Engl J Med 360 2009 765 773
10. M. Kool, J. Koster, J. Bunt, and et al. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features PLoS ONE 3 2008 e3088
11. M.E. Hegi, A.C. Diserens, T. Gorlia, and et al. MGMT gene silencing and benefit from temozolomide in glioblastoma N Engl J Med 352 2005 997 1003
12. H.J. Scherer A critical review: the pathology of cerebral gliomas J Neurol Psychiatry 3 1940 147 177
13. K. Watanabe, O. Tachibana, K. Sata, and et al. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas Brain Pathol 6 1996 217 223 [discussion 23-4]
14. A. Korshunov, R. Sycheva, and A. Golanov Genetically distinct and clinically relevant subtypes of glioblastoma defined by array-based comparative genomic hybridization (array-CGH) Acta Neuropathol 111 2006 465 474
15. E.A. Maher, F.B. Furnari, R.M. Bachoo, and et al. Malignant glioma: genetics and biology of a grave matter Genes Dev 15 2001 1311 1333
16. H.S. Phillips, S. Kharbanda, R. Chen, and et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis Cancer Cell 9 2006 157 173
17. R.G. Verhaak, K.A. Hoadley, E. Purdom, and et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1 Cancer Cell 17 2010 98 110
18. J.T. Huse, E. Holland, and L.M. DeAngelis Glioblastoma: molecular analysis and clinical implications Annu Rev Med 64 2013 59 70
19. L.A. Gravendeel, M.C. Kouwenhoven, O. Gevaert, and et al. Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology Cancer Res 69 2009 9065 9072
20. G. Toedt, S. Barbus, M. Wolter, and et al. Molecular signatures classify astrocytic gliomas by IDH1 mutation status Int J Cancer 128 2011 1095 1103
21. C.E. Pelloski, K.V. Ballman, A.F. Furth, and et al. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma J Clin Oncol 25 2007 2288 2294
22. D.A. Gutman, L.A. Cooper, S.N. Hwang, and et al. MR imaging predictors of molecular profile and survival: Multi-institutional study of the TCGA glioblastoma data set Radiology 267 2013 560 569
23. H. Colman, L. Zhang, E.P. Sulman, and et al. A multigene predictor of outcome in glioblastoma Neuro Oncol 12 2010 49 57
24. L.A. Cooper, D.A. Gutman, Q. Long, and et al. The proneural molecular signature is enriched in oligodendrogliomas and predicts improved survival among diffuse gliomas PLoS ONE 5 2010 e12548
25. F. Ducray, A. Idbaih, A. de Reynies, and et al. Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile Mol Cancer 7 2008 41
26. A.M. Sonabend, M. Bansal, P. Guarnieri, and et al. The transcriptional regulatory network of proneural glioma determines the genetic alterations selected during tumor progression Cancer Res 74 2014 1440 1451
27. N. Saito, J. Fu, S. Zheng, and et al. A high Notch pathway activation predicts response to gamma secretase inhibitors in proneural subtype of glioma tumor-initiating cells Stem Cells 32 2014 301 312
28. K.L. McDonald, J. McDonnell, A. Muntoni, and et al. Presence of alternative lengthening of telomeres mechanism in patients with glioblastoma identifies a less aggressive tumor type with longer survival J Neuropathol Exp Neurol 69 2010 729 736
29. R. Mahabir, M. Tanino, A. Elmansuri, and et al. Sustained elevation of Snail promotes glial-mesenchymal transition after irradiation in malignant glioma Neuro Oncol 16 2014 671 685
30. J.V. Joseph, S. Conroy, T. Tomar, and et al. TGF-beta is an inducer of ZEB1-dependent mesenchymal transdifferentiation in glioblastoma that is associated with tumor invasion Cell Death Dis 5 2014 e1443
31. B. Lv, X. Yang, S. Lv, and et al. CXCR4 signaling induced epithelial-mesenchymal transition by PI3K/AKT and ERK pathways in glioblastoma Mol Neurobiol 2014 [Epub ahead of print]
32. J.K. Myung, S.A. Choi, S.K. Kim, and et al. Snail plays an oncogenic role in glioblastoma by promoting epithelial mesenchymal transition Int J Clin Exp Pathol 7 2014 1977 1987
33. P. Mao, K. Joshi, J. Li, and et al. Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3 Proc Natl Acad Sci U S A 110 2013 8644 8649
34. K.P. Bhat, K.L. Salazar, V. Balasubramaniyan, and et al. The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma Genes Dev 25 2011 2594 2609
35. M.S. Carro, W.K. Lim, M.J. Alvarez, and et al. The transcriptional network for mesenchymal transformation of brain tumours Nature 463 2010 318 325
36. X. Guan, J. Vengoechea, S. Zheng, and et al. Molecular subtypes of glioblastoma are relevant to lower grade glioma PLoS ONE 9 2014 e91216
37. D.D. Gonda, V.J. Cheung, K.A. Muller, and et al. The Cancer Genome Atlas expression profiles of low-grade gliomas Neurosurg Focus 36 2014 E23
38. R. Gupta, R. Webb-Myers, S. Flanagan, and et al. Isocitrate dehydrogenase mutations in diffuse gliomas: clinical and aetiological implications J Clin Pathol 64 2011 835 844
39. J. Balss, J. Meyer, W. Mueller, and et al. Analysis of the IDH1 codon 132 mutation in brain tumors Acta Neuropathol 116 2008 597 602
40. C. Hartmann, B. Hentschel, W. Wick, and et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas Acta Neuropathol 120 2010 707 718
41. K. Ichimura, D. Pearson, S. Kocialkowski, and et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas Neuro Oncol 11 2009 341 347
42. H. Yan, D.W. Parsons, G. Jin, and et al. IDH1 and IDH2 mutations in gliomas N Engl J Med 360 2009 765 773
43. L. Dang, D.W. White, S. Gross, and et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate Nature 462 2009 739 744
44. S.V. Liubinas, G.M. D'Abaco, B.M. Moffat, and et al. IDH1 mutation is associated with seizures and protoplasmic subtype in patients with low-grade gliomas Epilepsia 55 2014 1438 1443
45. F. Stockhammer, M. Misch, H.J. Helms, and et al. IDH1/2 mutations in WHO grade II astrocytomas associated with localization and seizure as the initial symptom Seizure 21 2012 194 197
46. H.J. Dubbink, W. Taal, R. van Marion, and et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide Neurology 73 2009 1792 1795
47. H. Ohgaki, and P. Kleihues The definition of primary and secondary glioblastoma Clin Cancer Res 19 2013 764 772
48. Y. Jiao, P.J. Killela, Z.J. Reitman, and et al. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas Oncotarget 3 2012 709 722
49. P. Baumgarten, P.N. Harter, M. Tonjes, and et al. Loss of FUBP1 expression in gliomas predicts FUBP1 mutation and is associated with oligodendroglial differentiation, IDH1 mutation and 1p/19q loss of heterozygosity Neuropathol Appl Neurobiol 40 2014 205 216
50. X.Y. Liu, N. Gerges, A. Korshunov, and et al. Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations Acta Neuropathol 124 2012 615 625
51. P.J. Killela, C.J. Pirozzi, P. Healy, and et al. Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas Oncotarget 5 2014 1515 1525
52. M. Chekenya, and G.J. Pilkington NG2 precursor cells in neoplasia: functional, histogenesis and therapeutic implications for malignant brain tumours J Neurocytol 31 2002 507 521
53. S. Turcan, D. Rohle, A. Goenka, and et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype Nature 483 2012 479 483
54. M. Toyota, N. Ahuja, M. Ohe-Toyota, and et al. CpG island methylator phenotype in colorectal cancer Proc Natl Acad Sci U S A 96 1999 8681 8686
55. H. Noushmehr, D.J. Weisenberger, K. Diefes, and et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma Cancer Cell 17 2010 510 522
56. C.W. Brennan, R.G. Verhaak, A. McKenna, and et al. The somatic genomic landscape of glioblastoma Cell 155 2013 462 477
57. H.A. Luchman, O.D. Stechishin, N.H. Dang, and et al. An in vivo patient-derived model of endogenous IDH1-mutant glioma Neuro Oncology 14 2012 184 191
58. X.W. Wang, M. Labussiere, S. Valable, and et al. IDH1(R132H) mutation increases U87 glioma cell sensitivity to radiation therapy in hypoxia BioMed Res Int 2014 2014 198697
59. J.B. Wang, D.F. Dong, M.D. Wang, and et al. IDH1 overexpression induced chemotherapy resistance and IDH1 mutation enhanced chemotherapy sensitivity in Glioma cells in vitro and in vivo Asian Pacific J Cancer Prevent 15 2014 427 432
60. A.N. Tran, A. Lai, S. Li, and et al. Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry Neuro Oncol 16 2014 414 420
61. H. Wakimoto, S. Tanaka, W.T. Curry, and et al. Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas Clin Cancer Res 20 2014 2898 2909
62. D. Rohle, J. Popovici-Muller, N. Palaskas, and et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells Science 340 2013 626 630
63. S. Nobusawa, T. Watanabe, P. Kleihues, and et al. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas Clin Cancer Res 15 2009 6002 6007
64. R.J. Molenaar, D. Verbaan, S. Lamba, and et al. The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone Neuro Oncol 16 2014 1263 1273
65. G. Minniti, C. Scaringi, A. Arcella, and et al. IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy J Neurooncol 118 2014 377 383
66. J. Cai, P. Yang, C. Zhang, and et al. ATRX mRNA expression combined with IDH1/2 mutational status and Ki-67 expression refines the molecular classification of astrocytic tumors: evidence from the whole transcriptome sequencing of 169 samples Oncotarget 5 2014 2551 2561
67. W.B. Pope, R.M. Prins, M. Albert Thomas, and et al. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy J Neurooncol 107 2012 197 205
68. A. Elkhaled, L.E. Jalbert, J.J. Phillips, and et al. Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas Sci Transl Med 4 2012 116ra5
69. I. Nakano, and H.I. Kornblum Methods for analysis of brain tumor stem cell and neural stem cell self-renewal Methods Mol Biol 568 2009 37 56
70. R. Galli, E. Binda, U. Orfanelli, and et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma Cancer Res 64 2004 7011 7021
71. S.K. Singh, I.D. Clarke, M. Terasaki, and et al. Identification of a cancer stem cell in human brain tumors Cancer Res 63 2003 5821 5828
72. N. Thon, K. Damianoff, J. Hegermann, and et al. Presence of pluripotent CD133(+) cells correlates with malignancy of gliomas Mol Cell Neurosci 43 2010 51 59
73. F. Zeppernick, R. Ahmadi, B. Campos, and et al. Stem cell marker CD133 affects clinical outcome in glioma patients Clin Cancer Res 14 2008 123 129
74. M. Zhang, T. Song, L. Yang, and et al. Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients J Exp Clin Cancer Res 27 2008 85
75. P. Metellus, I. Nanni-Metellus, C. Delfino, and et al. Prognostic impact of CD133 mRNA expression in 48 glioblastoma patients treated with concomitant radiochemotherapy: a prospective patient cohort at a single institution Ann Surg Oncol 18 2011 2937 2945
76. C. Lottaz, D. Beier, K. Meyer, and et al. Transcriptional profiles of CD133+ and CD133- glioblastoma-derived cancer stem cell lines suggest different cells of origin Cancer Res 70 2010 2030 2040
77. K.M. Joo, S.Y. Kim, X. Jin, and et al. Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas Lab Invest 88 2008 808 815
78. L. Ricci-Vitiani, R. Pallini, L.M. Larocca, and et al. Mesenchymal differentiation of glioblastoma stem cells Cell Death Differ 15 2008 1491 1498
79. D. Beier, P. Hau, M. Proescholdt, and et al. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles Cancer Res 67 2007 4010 4015
80. I. Nakano Stem cell signature in glioblastoma: therapeutic development for a moving target J Neurosurg 122 2015 324 330
81. Q. Liu, D.H. Nguyen, Q. Dong, and et al. Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors J Neurooncol 94 2009 1 19
82. J. Wang, P.O. Sakariassen, O. Tsinkalovsky, and et al. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells Int J Cancer 122 2008 761 768
83. A. Soeda, M. Park, D. Lee, and et al. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha Oncogene 28 2009 3949 3959
84. K. Savary, D. Caglayan, L. Caja, and et al. Snail depletes the tumorigenic potential of glioblastoma Oncogene 32 2013 5409 5420
85. M. Baysan, K. Woolard, S. Bozdag, and et al. Micro-environment causes reversible changes in DNA methylation and mRNA expression profiles in patient-derived glioma stem cells PLoS One 9 2014 e94045
86. J. Lee, S. Kotliarova, Y. Kotliarov, and et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines Cancer Cell 9 2006 391 403
87. N. Montano, T. Cenci, M. Martini, and et al. Expression of EGFRvIII in glioblastoma: prognostic significance revisited Neoplasia 13 2011 1113 1121
88. A. Schulte, H.S. Gunther, T. Martens, and et al. Glioblastoma stem-like cell lines with either maintenance or loss of high-level EGFR amplification, generated via modulation of ligand concentration Clin Cancer Res 18 2012 1901 1913
89. M.M. Inda, R. Bonavia, A. Mukasa, and et al. Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma Genes Dev 24 2010 1731 1745
90. J.R. Molina, Y. Hayashi, C. Stephens, and et al. Invasive glioblastoma cells acquire stemness and increased Akt activation Neoplasia 12 2010 453 463
91. H.J. Jun, J. Acquaviva, D. Chi, and et al. Acquired MET expression confers resistance to EGFR inhibition in a mouse model of glioblastoma multiforme Oncogene 31 2012 3039 3050
92. Y. Wei, Y. Jiang, F. Zou, and et al. Activation of PI3K/Akt pathway by CD133-p85 interaction promotes tumorigenic capacity of glioma stem cells Proc Natl Acad Sci U S A 110 2013 6829 6834
93. C.J. Sandberg, G. Altschuler, J. Jeong, and et al. Comparison of glioma stem cells to neural stem cells from the adult human brain identifies dysregulated Wnt- signaling and a fingerprint associated with clinical outcome Exp Cell Res 319 2013 2230 2243
94. X. Fan, L. Khaki, T.S. Zhu, and et al. NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts Stem Cells 28 2010 5 16
95. A. Schulte, H.S. Gunther, H.S. Phillips, and et al. A distinct subset of glioma cell lines with stem cell-like properties reflects the transcriptional phenotype of glioblastomas and overexpresses CXCR4 as therapeutic target Glia 59 2011 590 602
96. M. Ehtesham, K.Y. Mapara, C.B. Stevenson, and et al. CXCR4 mediates the proliferation of glioblastoma progenitor cells Cancer Lett 274 2009 305 312
97. Y.F. Ping, X.H. Yao, J.Y. Jiang, and et al. The chemokine CXCL12 and its receptor CXCR4 promote glioma stem cell-mediated VEGF production and tumour angiogenesis via PI3K/AKT signalling J Pathol 224 2011 344 354
98. P. Brescia, B. Ortensi, L. Fornasari, and et al. CD133 is essential for glioblastoma stem cell maintenance Stem Cells 31 2013 857 869
99. N.K. Gerber, A. Goenka, S. Turcan, and et al. Transcriptional diversity of long-term glioblastoma survivors Neuro Oncol 16 2014 1186 1195
100. G. Reifenberger, R.G. Weber, V. Riehmer, and et al. Molecular characterization of long-term survivors of glioblastoma using genome- and transcriptome-wide profiling Int J Cancer 135 2014 1822 1831
101. W. Wick, M. Platten, C. Meisner, and et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial Lancet Oncol 13 2012 707 715
102. M. Le Mercier, D. Hastir, X. Moles Lopez, and et al. A simplified approach for the molecular classification of glioblastomas PLoS One 7 2012 e45475
103. J.M. Angelastro, and M.W. Lame Overexpression of CD133 promotes drug resistance in C6 glioma cells Mol Cancer Res 8 2010 1105 1115
104. S. Warrier, P. Pavanram, D. Raina, and et al. Study of chemoresistant CD133+ cancer stem cells from human glioblastoma cell line U138MG using multiple assays Cell Biol Int 36 2012 1137 1143
105. J. He, Z. Shan, L. Li, and et al. Expression of glioma stem cell marker CD133 and O6-methylguanine-DNA methyltransferase is associated with resistance to radiotherapy in gliomas Oncol Rep 26 2011 1305 1313
106. M. Jamal, B.H. Rath, P.S. Tsang, and et al. The brain microenvironment preferentially enhances the radioresistance of CD133(+) glioblastoma stem-like cells Neoplasia 14 2012 150 158
107. S. Bao, Q. Wu, R.E. McLendon, and et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response Nature 444 2006 756 760
108. D. Lemke, M. Weiler, J. Blaes, and et al. Primary glioblastoma cultures: can profiling of stem cell markers predict radiotherapy sensitivity? J Neurochem 2014 [Epub ahead of print]
109. W.Y. Cheng, J.J. Kandel, D.J. Yamashiro, and et al. A multi-cancer mesenchymal transition gene expression signature is associated with prolonged time to recurrence in glioblastoma PLoS One 7 2012 e34705
110. F. Jin, C. Gao, L. Zhao, and et al. Using CD133 positive U251 glioblastoma stem cells to establish nude mice model of transplanted tumor Brain Res 1368 2011 82 90
111. K.P. Bhat, V. Balasubramaniyan, B. Vaillant, and et al. Mesenchymal differentiation mediated by NF-kappaB promotes radiation resistance in glioblastoma Cancer Cell 24 2013 331 346
112. R. Martinez, V. Rohde, and G. Schackert Different molecular patterns in glioblastoma multiforme subtypes upon recurrence J Neurooncol 96 2010 321 329
113. A. Saxena, L.M. Shriml, M. Dean, and et al. Comparative molecular genetic profiles of anaplastic astrocytomas/glioblastomas multiforme and their subsequent recurrences Oncogene 18 1999 1385 1390
114. J.R. Shapiro, and W.R. Shapiro The subpopulations and isolated cell types of freshly resected high grade human gliomas: their influence on the tumor's evolution in vivo and behavior and therapy in vitro Cancer Metastasis Rev 4 1985 107 124
115. A. Sottoriva, I. Spiteri, S.G. Piccirillo, and et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics Proc Natl Acad Sci U S A 110 2013 4009 4014
116. S.G. Piccirillo, R. Combi, L. Cajola, and et al. Distinct pools of cancer stem-like cells coexist within human glioblastomas and display different tumorigenicity and independent genomic evolution Oncogene 28 2009 1807 1811
117. S.N. Popova, M. Bergqvist, A. Dimberg, and et al. Subtyping of gliomas of various WHO grades by the application of immunohistochemistry Histopathology 64 2014 365 379
118. R. Li, K. Gao, H. Luo, and et al. Identification of intrinsic subtype-specific prognostic microRNAs in primary glioblastoma J Exp Clin Cancer Res 33 2014 9
119. B.E. Johnson, T. Mazor, C. Hong, and et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma Science 343 2014 189 193